| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
IDT307 targets the dopamine transporter (DAT) as a fluorescent substrate. It is also a substrate for the plasma membrane monoamine transporter (PMAT). The compound does not target a specific enzyme but rather serves as a fluorescent probe for studying transporter-mediated uptake of organic cations.
|
|---|---|
| ln Vitro |
IDT307, which is transported into the apical membrane (CSF-facing) of CP epithelial cells, is an analog of the organic cationic MPP+ and is susceptible to inhibition by quinine, a PMAT inhibitor [1]. Pmat knockout mice's CP tissues showed a significant 70% reduction in IDT307 uptake and intracellular accumulation [1].
The in vitro activity of IDT307 is its function as a fluorescent substrate for DAT and PMAT. The compound is taken up by cells expressing these transporters, and its fluorescence can be detected and quantified. IDT307 is transported into choroid plexus epithelial cells at the apical membrane, and this transport is sensitive to inhibition by the PMAT inhibitor quinine. The compound enables the study of transporter function and the screening of transporter inhibitors. |
| ln Vivo |
In vivo, IDT307 has been used to study transporter function in animal models. In Pmat gene knockout mice, choroid plexus tissue uptake of IDT307 and its accumulation in cells is significantly reduced, with a decrease of approximately 70%. This demonstrates the in vivo utility of IDT307 as a probe for studying PMAT function.
|
| Enzyme Assay |
In vitro transporter assays for IDT307 involve incubating cells expressing DAT or PMAT with the fluorescent substrate in appropriate buffer conditions. The uptake of the compound into cells is measured by quantifying the fluorescence signal using a fluorescence microplate reader, flow cytometry, or fluorescence microscopy. Transport can be inhibited by known transporter inhibitors (such as quinine for PMAT) to confirm specificity.
|
| Cell Assay |
For in vitro cellular experiments, IDT307 is dissolved in DMSO and diluted in cell culture medium. Cells expressing DAT or PMAT are incubated with the compound at appropriate concentrations for a defined period. After washing to remove extracellular dye, cells are analyzed by fluorescence microscopy or flow cytometry to measure the intracellular fluorescence. The uptake can be quantified and compared between different cell types or treatment conditions.
|
| Animal Protocol |
For in vivo animal experiments, IDT307 has been used in studies with Pmat gene knockout mice. The compound can be administered to animal models to study transporter function in tissues such as the choroid plexus. Tissue uptake and accumulation can be measured by fluorescence imaging or by extracting and quantifying the dye from tissues.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of IDT307 have not been extensively characterized. The compound has a molecular weight of 340.20 g/mol and a molecular formula of C₁₄H₁₇IN₂. It should be stored under appropriate conditions, protected from light.
|
| Toxicity/Toxicokinetics |
Toxicological data for IDT307 has not been systematically evaluated, as the compound is intended for research applications only and not for therapeutic use. Standard laboratory safety precautions should be observed when handling this chemical reagent.
|
| References | |
| Additional Infomation |
IDT307 (APP+) is a cationic fluorescent pyridinium dye and an analog of MPP+ that serves as a specific fluorescent substrate for DAT. It is transported into choroid plexus epithelial cells and is sensitive to PMAT inhibition. The compound is used in neuroscience research to study monoamine transport and has no clinical or therapeutic applications.
|
| Molecular Formula |
C14H17IN2
|
|---|---|
| Molecular Weight |
340.20
|
| Exact Mass |
340.044
|
| CAS # |
1141-41-9
|
| PubChem CID |
13227270
|
| Appearance |
Yellow to orange solid powder
|
| Melting Point |
180-182 °C
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
17
|
| Complexity |
199
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C[N+]1=CC=C(C=C1)C2=CC=C(C=C2)N(C)C.[I-]
|
| InChi Key |
CAMWVBRDIKKGII-UHFFFAOYSA-M
|
| InChi Code |
InChI=1S/C14H17N2.HI/c1-15(2)14-6-4-12(5-7-14)13-8-10-16(3)11-9-13;/h4-11H,1-3H3;1H/q+1;/p-1
|
| Chemical Name |
N,N-dimethyl-4-(1-methylpyridin-1-ium-4-yl)aniline;iodide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 62.5 mg/mL (183.72 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (6.11 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (6.11 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9394 mL | 14.6972 mL | 29.3945 mL | |
| 5 mM | 0.5879 mL | 2.9394 mL | 5.8789 mL | |
| 10 mM | 0.2939 mL | 1.4697 mL | 2.9394 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
